Thomas Garner
First SEC filing: Feb. 12, 2024 · Latest: Feb. 12, 2024
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 6, 2026 | ACAD | A | 97,947 | · | · | 97,947 Direct | · | Acquired | (price as of 2026-10-02) |
| March 6, 2026 | ACAD | A | 28,493 | · | · | 28,493 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 9, 2024 | ACAD | A | 235,849 | · | · | 235,849 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 9, 2024 | ACAD | A | 45,372 | · | · | 45,372 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 8, 2024 | LXRX | A | 227,130 | · | · | 227,130 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 8, 2024 | LXRX | A | 227,130 | · | · | 227,130 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 9, 2023 | LXRX | A | 248,923 | · | · | 248,923 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 6, 2026 | ACAD | Stock Option (Right to Buy) | Common Stock | $22.16 | March 5, 2036 | 97,947 | Acquired |
| March 6, 2026 | ACAD | Restricted Stock Units | Common Stock | · | · | 28,493 | Acquired |
| Dec. 9, 2024 | ACAD | Stock Option (Right to Buy) | Common Stock | $18.76 | Dec. 8, 2034 | 235,849 | Acquired |
| Dec. 9, 2024 | ACAD | Restricted Stock Units | Common Stock | · | · | 45,372 | Acquired |
| Feb. 8, 2024 | LXRX | Stock Option (Right to Buy) | Common Stock | $2.15 | Feb. 8, 2034 | 227,130 | Acquired |
| Feb. 8, 2024 | LXRX | Restricted Stock Units | Common Stock | · | · | 227,130 | Acquired |
| Oct. 9, 2023 | LXRX | Stock Option (Right to Buy) | Common Stock | $1.08 | Oct. 9, 2033 | 248,923 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $471,032 | · | $488,330 | · | · | · | $627,676 | $1,987,425 |
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $525,000 | · | · | · | $299,250 | · | $32,773 | $857,023 |
| 2024 | $32,813 | · | $851,179 | $2,586,910 | · | · | $200,049 | $3,670,951 |
| 2023 | · | · | · | · | · | · | · | · |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.